Key Facts

- Sponsored by ResMed, SERVE-HF is, to date, the largest randomised controlled study in the field of sleep-disordered breathing related to chronic heart failure to investigate if treatment of predominantly central sleep apnea (CSA) improves survival and the hospitalisation rate of patients with stable heart failure.
- The study is being conducted across 80 centres throughout Europe and Australia.
- Results from SERVE-HF are expected in 2016.
- Findings of the study may have significant therapeutic implications by conclusively answering the question: what are the benefits of treating CSA in heart failure patients with PaceWave™ Adaptive Servo-Ventilation (ASV) therapy?
- The study seeks to assess impact of PaceWave™ ASV therapy on mortality, hospitalisation rate, cardiac function, biomarkers and quality of life.
- A health economics analysis will also be performed to assess the cost/benefits ratio of PaceWave™ ASV therapy in heart failure.

Serve-HF

- Sponsored by ResMed, SERVE-HF is, to date, the largest randomised controlled study in the field of sleep-disordered breathing related to chronic heart failure to investigate if treatment of predominantly central sleep apnea (CSA) improves survival and hospitalisation rate of patients with stable heart failure.

In 2013 SERVE-HF finished recruitment, with its 1,325th patient enrolled.

Rationale for SERVE-HF

- There are an estimated 14 million patients suffering from heart failure in Europe, which is likely to rise as life expectancy increases.¹,²

- Among multiple heart failure co-morbidities, sleep-disordered breathing (SDB) is the most common. However it remains the least recognised by cardiologists.³

- Central sleep apnea with Cheyne–Stokes respiration (CSA-CSR) is a common type of central sleep-disordered breathing in patients with heart failure, occurring in 30-50 percent of them.⁴,⁵

- Studies have shown that central SDB is associated with increased mortality, cardiac hospital readmissions and lower quality of life in heart failure patients.⁶
• Effective treatment of central SDB can improve cardiac function and survival in these patients. However, to date, no large-scale randomised trial has been conducted to conclusively demonstrate the precise benefits of longer-term therapy on multiple outcomes.

• SERVE-HF is seeking to show the extent of benefit of PaceWave™ ASV therapy on patients with heart failure and central sleep-disordered breathing as well as the cost/benefit ratio of the therapy.

SERVE-HF study design

• The design of the SERVE-HF trial was developed in collaboration with a Steering Committee of highly experienced experts in the field of both heart failure and sleep medicine.

• Co-principal investigators of SERVE-HF are:
  o Prof. Martin Cowie, National Heart and Lung Institute (NHLI), Brompton Campus, London, UK
  o Prof. Helmut Teschler, Department of Respiratory Medicine, Ruhrlandklinik, Essen, Germany

• The first patient was randomised in 2008 and the study is likely to complete in Q4 2015.

• Patients will be followed up for an average of ~54 months (minimum 24 months – maximum 84 months).

Primary endpoints include time to:
  o All-cause death
  o Unplanned hospitalisation for worsening chronic heart failure

Secondary endpoints include:
  o Changes in general and disease-specific quality of life and in heart failure symptoms
  o Change in six minute walk distance
  o Changes in cardiac function
  o Changes in cognitive function
  o Changes in biomarkers

Outcomes

• SERVE-HF is an important randomised controlled trial that will assess, for the first time, whether treating SDB with PaceWave™ ASV can reduce morbidity and mortality in patients with heart failure.

• The findings may have important implications for individualised therapeutic strategies targeted at reducing the morbidity, mortality and economic burden of heart failure.

• Results may also offer the opportunity to review current practices in the diagnosis and treatment of SDB in heart failure.
References